Effect of light treatment on sleep and behavior in patients with Alzheimer`s disease

A Study on the Effect of Timed Light on Sleep and Behavior in Patients with Alzheimer`s Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005282

Enrollment

Registered

2020-08-04

Start date

2017-04-01

Completion date

Unknown

Last updated

2020-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Home-based 1 hour blue enriched light therapy (LT) (Litebook ® EDGE™

Litebook Company Ltd, Alberta, Canada) for 2 weeks was applied at 9-10 h following the DLMO for each patient. The control group is kept to wear blue-blocked glasses (Litebook Company Ltd) during timed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient eligibility criteria included a diagnosis of probable or possible AD for major neurocognitive disorder, a CDR score ranging from 0.5 to 2, a sleep disturbance verified by a score of 5 or greater on the Pittsburgh Sleep Quality Index (PSQI) 25 and/or by one or more complaints among difficulty initiating sleep (DIS), difficulty maintaining sleep (DMS), and early morning awakening (EMA) for three or more days per week.

Exclusion criteria

Exclusion criteria: 1) current substance related disorders, depressive disorders, or other psychiatric disorders by DSM-5; 2) current medical illness including liver cirrhosis, chronic pulmonary disease, cancer, uncontrolled diabetes, and uncontrolled hypertension; 3) being suspected or diagnosed with primary sleep disorders except for insomnia disorder (i.e., restless legs syndrome, sleep-disordered breathing disorder; hypersomnia, or narcolepsy); 4) a prior history of cerebrovascular disease or central nervous system (CNS) disease, or evidence of CNS injury; 5) current use of any medication affecting their circadian rhythms (i.e., CircadinR); 6) changes in type or dose of taking hypnotics or CNS active drugs for the study period; 7) significant impairment of hearing ability, visual acuity, or language ability which hindered the completion of neurocognitive tests; 8) abnormalities in complete blood cell count, liver function test, urine analysis, electrocardiogram (ECG), or chest X-ray; AND 9) pupillary abnormalities on a neuro-ophthalmological examination.

Design outcomes

Primary

Measure	Time frame
(1) Subjective sleep quality (Pittsburgh Sleep Quality Index), (2) Cognitive function (Mini-Mental State Examination in the Korean version of the CERAD assessment packet, Trail making test, Stroop Test, Digit Span Test, Visual Analog Scale), (3) Actigaphy measurements ( sleep parameters, sleep-wake rhythms, light exposure rhythms), (4) Korean version of Cornell Scale for Depression in Dementia, (5) Korean version of Neuropsychiatric Inventory,Korean version of Zarit Burden Interview	—

Measure

Time frame

(1) Subjective sleep quality (Pittsburgh Sleep Quality Index), (2) Cognitive function (Mini-Mental State Examination in the Korean version of the CERAD assessment packet, Trail making test, Stroop Test, Digit Span Test, Visual Analog Scale), (3) Actigaphy measurements ( sleep parameters, sleep-wake rhythms, light exposure rhythms), (4) Korean version of Cornell Scale for Depression in Dementia, (5) Korean version of Neuropsychiatric Inventory,Korean version of Zarit Burden Interview

—

Secondary

Measure	Time frame
(1) Korean version of Epworth Sleepiness Scale, (2) Activities of Daily Living, (3) Korean version of the Geriatric Depression Scale	—

Countries

Korea, Republic of

Contacts

Public ContactSeong Jae Kim

Kangwon National University Hospital

Outcome results